NCT07892339Not yet recruitingPhase 3
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis: A Prospective Randomized Controlled Study.
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat flexural and/or genital psoriasis in adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment. The main questions it aims to answer is: * Does crisaborole 2% ointment work effectively in flexural and/or genital psoriasis in adults? * is crisaborole 2% ointment well tolerated in flexural and/or genital psoriasis in adults? * Is crisaborole 2% ointment comparable to tacrolimus 0.1% ointment in terms of efficacy and safety in flexural and/or genital psoriasis in adults? Researchers will compare crisaborole 2% ointment to tacrolimus 0.1% ointment to see if crisaborole works as effective and is as well-tolerated. Participants will: * apply topical crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily for 6 weeks to plaques of flexural and/or genital psoriasis. * Visit the clinic once every 2 weeks for checkups and photography. * Keep a diary of their symptoms.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 17 Oct 2026
- Start date
- 25 Oct 2026
- Primary completion date
- 13 Dec 2026
- Lead sponsor
- Cairo University
- Diseases
- Psoriasis
- NCT number
- NCT07892339
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 40
- From 25 Oct 2026 to the primary completion date, 13 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinical or mycological evidence of concurrent fungal or bacterial infection in the target area.
- Immunosuppressive conditions or concurrent immunosuppressive therapy
- Use of phototherapy within 1 month prior to enrollment.
- Use of any topical antipsoriatic therapies within 1 month prior to enrollment.
- Use of any systemic antipsoriatic therapies within 3 months for conventional systemic agents or biologics, extending to 6 months for patients previously on acitretin.
Other illness
- A documented history of hypersensitivity or severe cutaneous reactions to any component of the active study medications (crisaborole or tacrolimus).
Other
- Generalized Plaque Psoriasis ≥ 10% BSA and /or PASI ≥ 10.
- Erythrodermic and Pustular Psoriasis.
- Associated PSA or Other Co-morbidities.
- Pregnant and lactating females.
- Pre-existing signs of skin atrophy, telangiectasia or striae in the target area.
Who the study is looking for
- Adults (≥18 years) of both genders.
- A confirmed clinical and dermoscopic diagnosis of intertriginous and/or anogenital psoriasis.
- PASI\<10% and /or BSA\<10%.
- Target Lesion Severity Score (TLSS) ≥ 3.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine Cairo University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.